Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Director Paul J. Hastings sold 1,044 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total value of $37,740.60. Following the transaction, the director now owns 3,518 shares of the company’s stock, valued at $127,175.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) traded down 3.38% during trading on Friday, reaching $35.75. The company’s stock had a trading volume of 354,490 shares. The company’s 50 day moving average price is $41.49 and its 200 day moving average price is $45.06. Pacira Pharmaceuticals, Inc. has a 12 month low of $29.95 and a 12 month high of $58.95. The firm’s market cap is $1.44 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.06. The firm had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.21 earnings per share. On average, equities analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.16) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/27/insider-selling-pacira-pharmaceuticals-inc-pcrx-director-sells-37740-60-in-stock.html.

Several research firms have issued reports on PCRX. HC Wainwright set a $59.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, May 6th. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 2nd. Mizuho restated a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Wedbush restated an “outperform” rating and set a $87.00 target price on shares of Pacira Pharmaceuticals in a report on Wednesday. Finally, BidaskClub cut Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $53.92.

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares during the last quarter. Teachers Advisors LLC boosted its stake in Pacira Pharmaceuticals by 6.2% in the fourth quarter. Teachers Advisors LLC now owns 62,854 shares of the company’s stock valued at $2,030,000 after buying an additional 3,658 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in Pacira Pharmaceuticals during the first quarter valued at $2,736,000. Nationwide Fund Advisors boosted its stake in Pacira Pharmaceuticals by 147.4% in the first quarter. Nationwide Fund Advisors now owns 56,190 shares of the company’s stock valued at $2,562,000 after buying an additional 33,482 shares during the last quarter. Finally, Fisher Asset Management LLC purchased a new stake in Pacira Pharmaceuticals during the first quarter valued at $285,000.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.